Your browser doesn't support javascript.
loading
Structure-Guided Design of a "Bump-and-Hole" Bromodomain-Based Degradation Tag.
Nowak, Radoslaw P; Xiong, Yuan; Kirmani, Nadia; Kalabathula, Joann; Donovan, Katherine A; Eleuteri, Nicholas A; Yuan, J Christine; Fischer, Eric S.
Affiliation
  • Nowak RP; Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • Xiong Y; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
  • Kirmani N; Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • Kalabathula J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
  • Donovan KA; Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • Eleuteri NA; Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • Yuan JC; Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • Fischer ES; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
J Med Chem ; 64(15): 11637-11650, 2021 08 12.
Article in En | MEDLINE | ID: mdl-34279939
ABSTRACT
Chemical biology tools to modulate protein levels in cells are critical to decipher complex biology. Targeted protein degradation offers the potential for rapid and dose-dependent protein depletion through the use of protein fusion tags toward which protein degraders have been established. Here, we present a newly developed protein degradation tag BRD4BD1L94V along with the corresponding cereblon (CRBN)-based heterobifunctional degrader based on a "bump-and-hole" approach. The resulting compound XY-06-007 shows a half-degradation concentration (DC50, 6 h) of 10 nM against BRD4BD1L94V with no degradation of off-targets, as assessed by whole proteome mass spectrometry, and demonstrates suitable pharmacokinetics for in vivo studies. We demonstrate that BRD4BD1L94V can be combined with the dTAG approach to achieve simultaneous degrader-mediated depletion of their respective protein fusions. This orthogonal system complements currently available protein degradation tags and enables investigation into the consequences resulting from rapid degradation of previously undruggable disease codependencies.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Transcription Factors / Drug Design / Cell Cycle Proteins Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2021 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Transcription Factors / Drug Design / Cell Cycle Proteins Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2021 Document type: Article Affiliation country: United States
...